Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | UGT2B7 | P16662 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26077265 | 0.95 | CYP2D6 (0.44) | CYP2D6ALDH1A1NPSR1L3MBTL1THRB | |
| SCHEMBL21821549 | 0.91 | MGAM (0.43) | CYP2D6ALDH1A1L3MBTL1TSHRKMT2A | |
| SCHEMBL3602265 | 0.83 | SLC6A2 (0.42) | CYP2D6ALDH1A1L3MBTL1TSHRUGT2B7 | |
| SCHEMBL28262624 | 0.82 | CYP2D6 (0.45) | CYP2D6ALDH1A1NPSR1L3MBTL1THRB | |
| SCHEMBL27545267 | 0.82 | CYP2D6 (0.47) | CYP2D6ALDH1A1NPSR1L3MBTL1THRB | |
| SCHEMBL22963812 | 0.82 | CYP2D6 (0.47) | CYP2D6ALDH1A1NPSR1L3MBTL1THRB | |
| SCHEMBL5682017 | 0.82 | CYP2D6 (0.47) | CYP2D6ALDH1A1NPSR1L3MBTL1THRB | |
| SCHEMBL13681637 | 0.82 | CYP2D6 (0.47) | CYP2D6ALDH1A1NPSR1L3MBTL1THRB | |
| SCHEMBL17865084 | 0.81 | EPHX2 (0.46) | ALDH1A1NPSR1L3MBTL1KMT2ATP53 | |
| Hydrochloric Acid SCHEMBL30562189 | 0.81 | SMYD3 (0.44) | CYP2D6ALDH1A1L3MBTL1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771358-B2 | Dihydropyrimidine compounds and their application in pharmaceuticals | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-09-26 | — | — | US | disclosed |
| US-20160347746-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-12-01 | — | — | US | disclosed |
| EP-2496682-A1 | DELIVERY PARTICLE | The Procter & Gamble Company (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011056935-A1 | DELIVERY PARTICLE | THE PROCTER & GAMBLE COMPANY (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20050065349-A1 | Asymmetric 1,4-reductions of and 1,4-additions to enoates and related systems | BUCHWALD STEPHEN L (US) | 2005-03-24 | — | — | US | disclosed |
| US-6787655-B2 | TRANSITION-METAL-CATALYZED ASYMMETRIC 1,4-ADDITION OF A NUCLEOPHILE, E.G., HYDRIDE, TO CYCLIC AND ACYCLIC ENOATES AND ENONES AND THE CATALYST CONTAINING A COPPER AND AN ASYMMETRIC BIDENTATE BISPHOSPHINE LIGAND | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2004-09-07 | — | — | US | disclosed |
| US-20030125563-A1 | Asymmetric 1,4-reductions of and 1,4-additions to enoates and related systems | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-03 | — | — | US | disclosed |
| US-6465664-B1 | CATALYZED WITH A TRANSITION METAL CATALYST COMPOSED OF A COPPER COMPOUND AND AN ASYMMETRIC LIGAND, SUCH AS A PHOSPHINE, A NUCLEOPHILE AND A BASE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2002-10-15 | — | — | US | disclosed |
| WO-2001019761-A2 | ASYMMETRIC 1,4-REDUCTIONS OF AND 1,4-ADDITIONS TO ENOATES AND RELATED SYSTEMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065349-A1 | Asymmetric 1,4-reductions of and 1,4-additions to enoates and related systems | APEX1, AP2A1, ENPP1 | CYP2D6 483/4885ALDH1A1 123/4885NPSR1 2910/4885 |
| US-20160347746-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | DPYD, SLC10A1, HPRT1 | CYP2D6 37/4885ALDH1A1 828/4885NPSR1 3221/4885 |
| US-20030125563-A1 | Asymmetric 1,4-reductions of and 1,4-additions to enoates and related systems | APEX1, AP2A1, ENPP1 | CYP2D6 483/4885ALDH1A1 123/4885NPSR1 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.